Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.
Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate from China’s National Medical Products Administration for its Oseltamivir Phosphate for Suspension, an over-the-counter oral antiviral formulation. The approval, following a review process that began with a marketing application in March 2024, confirms the product meets regulatory standards for quality, labeling and production, and requires a pre‑market GMP compliance inspection, paving the way for future commercialisation and potentially strengthening the company’s position in the influenza treatment market.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a China-based pharmaceutical manufacturer focused on chemical drugs and over-the-counter medicines. The company develops and produces formulations for both domestic and overseas markets, with a product portfolio that includes antiviral treatments and other therapeutic categories aligned with national medical regulations.
Average Trading Volume: 2,115,803
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.99B
For a thorough assessment of 0719 stock, go to TipRanks’ Stock Analysis page.